CoChat

Variations in the FRA10AC1 Fragile Site and 15q21 Are Associated with Cerebrospinal Fluid Aβ1-42 Level

Open access
Li, Qingqin S., Parrado, Antonio R., Samtani, Mahesh N., Narayan, Vaibhav A., Alzheimer’s Disease Neuroimaging Initiative · 2015 · PLOS ONE
Cited by 40

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

Proteolytic fragments of amyloid and post-translational modification of tau species in Cerebrospinal fluid (CSF) as well as cerebral amyloid deposition are important biomarkers for Alzheimer's Disease. We conducted genome-wide association study to identify genetic factors influencing CSF biomarker level, cerebral amyloid deposition, and disease progression. The genome-wide association study was performed via a meta-analysis of two non-overlapping discovery sample sets to identify genetic variants other than APOE ε4 predictive of the CSF biomarker level (Aβ1-42, t-Tau, p-Tau181P, t-Tau:Aβ1-42 ratio, and p-Tau181P:Aβ1-42 ratio) in patients enrolled in the Alzheimer's Disease Neuroimaging Initiative (ADNI) study. Loci passing a genome-wide significance threshold of P < 5 x 10-8 were followed-up for replication in an independent sample set. We also performed joint meta-analysis of both discovery sample sets together with the replication sample set. In the discovery phase, we identified variants in FRA10AC1 associated with CSF Aβ1-42 level passing the genome-wide significance threshold (directly genotyped SNV rs10509663 PFE = 1.1 x 10-9, imputed SNV rs116953792 PFE = 3.5 x 10-10), rs116953792 (Pone-sided = 0.04) achieved replication. This association became stronger in the joint meta-analysis (directly genotyped SNV rs10509663 PFE = 1.7 x 10-9, imputed SNV rs116953792 PFE = 7.6 x 10-11). Additionally, we identified locus 15q21 (imputed SNV rs1503351 PFE = 4.0 x 10-8) associated with CSF Aβ1-42 level. No other variants passed the genome-wide significance threshold for other CSF biomarkers in either the discovery sample sets or joint analysis. Gene set enrichment analyses suggested that targeted genes mediated by miR-33, miR-146, and miR-193 were enriched in various GWAS analyses. This finding is particularly important because CSF biomarkers confer disease susceptibility and may be predictive of the likelihood of disease progression in Alzheimer's Disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0134000

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Research works printed but not linked: 17

  1. 1998, Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group, Neurobiology of aging, 19, 109
  2. RA Frank, 2003, Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease, Neurobiology of aging, 24, 521
  3. MN Samtani, 2013, Disease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypes, British journal of clinical pharmacology, 75, 146, 10.1111/j.1365-2125.2012.04308.x · DOI · Paper page
  4. C Andersson, 2008, Increasing CSF phospho-tau levels during cognitive decline and progression to dementia, Neurobiology of aging, 29, 1466, 10.1016/j.neurobiolaging.2007.03.027 · DOI
  5. VK Ramanan, 2014, APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study, Molecular psychiatry, 19, 351, 10.1038/mp.2013.19 · DOI · Paper page
  6. X Hu, 2011, Genome-wide association study identifies multiple novel loci associated with disease progression in subjects with mild cognitive impairment, Translational psychiatry, 1, e54, 10.1038/tp.2011.50 · DOI
  7. N Rotllan, 2012, MicroRNA Regulation of Cholesterol Metabolism, Cholesterol, 2012, 847849, 10.1155/2012/847849 · DOI
  8. MM Carrasquillo, 2011, Replication of EPHA1 and CD33 associations with late-onset Alzheimer's disease: a multi-centre case-control study, Molecular neurodegeneration, 6, 54, 10.1186/1750-1326-6-54 · DOI · Paper page
  9. Y Kong, 2014, MicroRNA expression analysis of adult-onset Drosophila Alzheimer's disease model, Current Alzheimer research, 11, 882
  10. R Zhang, 2014, Screening of microRNAs associated with Alzheimer's disease using oxidative stress cell model and different strains of senescence accelerated mice, Journal of the neurological sciences, 338, 57, 10.1016/j.jns.2013.12.017 · DOI
  11. LL Wang, 2012, potential role of microRNA-146 in Alzheimer's disease: biomarker or therapeutic target?, The, 78, 398
  12. L Tan, 2013, Non-coding RNAs in Alzheimer's disease, Molecular neurobiology, 47, 382, 10.1007/s12035-012-8359-5 · DOI · Paper page
  13. YS Aulchenko, 2009, Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts, Nature genetics, 41, 47, 10.1038/ng.269 · DOI · Paper page
  14. J Marchini, 2010, Genotype imputation for genome-wide association studies, Nature reviews Genetics, 11, 499, 10.1038/nrg2796 · DOI · Paper page
  15. J Marchini, 2007, A new multipoint method for genome-wide association studies by imputation of genotypes, Nature genetics, 39, 906, 10.1038/ng2088 · DOI · Paper page
  16. BN Howie, 2009, A flexible and accurate genotype imputation method for the next generation of genome-wide association studies, PLoS genetics, 5, e1000529, 10.1371/journal.pgen.1000529 · DOI · Paper page
  17. S Purcell, 2007, PLINK: a tool set for whole-genome association and population-based linkage analyses, American journal of human genetics, 81, 559, 10.1086/519795 · DOI · Paper page

Cited by

Metadata

Authors
Li, Q. S., Parrado, A. R., Samtani, M. N., Narayan, V. A., & Initiative, A. D. N.
Venue
PLOS ONE
Published
2015-08-07
Volume
10
Issue
8
Pages
e0134000
ISSN
1932-6203 (ISSN-L)
OpenAlex
W1926182559
Cited by
40
References
22
FWCI
2.15
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.